Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Curr Top Microbiol Immunol. 2011;344:173–192. doi: 10.1007/82_2010_48

Figure 3.

Figure 3

DC s as targets for therapy. Cancer cells attract immature DC possibly through chemokines such as MIP3 alpha and/or SDF-1. The DC can then be either blocked or skewed in their maturation, for example by VEGF, leading to induction of polarized CD4+T cells that promote the expansion of cancer cells (pro-cancer) at the expense of CD8+T cells that can cause tumor regression (anti-cancer). An interesting strategy would be to rewire their molecular pathways from “pro-cancer” DCs into “anti-cancer” DCs for example with antibodies or DC activators.